Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Myriad Genetics Inc 322 NORTH 2200 WEST SALT LAKE CITY UT 84116 USA

www.myriad.com Employees: 2,700 P: 801-584-3600 F: 801-584-3640

Description:

Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company has more than 10 proprietary molecular diagnostic products in market. It has made significant progress in transition & expand the hereditary cancer market, diversify revenues by commercializing its new products, increase the company's international contribution by investing in large countries, gaining reimbursement for new products, increasing international RNA kit revenue and enhancing profitability. Its flagship product BRACAnalysis offers a comprehensive analysis of BRCA1 and BRCA2 genes to assess a woman's risk of hereditary breast and ovarian cancers. Its major products are myRisk Hereditary Cancer, myPlan Lung Cancer and molecular diagnostic test myPath Melanoma. It acquired Counsyl, Inc. The company has 2 operating units: Molecular diagnostic & Pharmaceutical and clinical services.

Key Statistics

Overview:

Market Capitalization, $K 1,216,228
Enterprise Value, $K 1,122,628
Shares Outstanding, K 91,035
Annual Sales, $ 753,200 K
Annual Net Income, $ -263,300 K
Last Quarter Sales, $ 213,300 K
Last Quarter Net Income, $ -22,100 K
EBIT, $ -102,000 K
EBITDA, $ -40,100 K
60-Month Beta 1.87
% of Insider Shareholders 2.10%
% of Institutional Shareholders 99.02%
Float, K 89,123
% Float 97.90%
Short Volume Ratio 0.55

Growth:

1-Year Return -34.25%
3-Year Return -51.04%
5-Year Return -50.11%
5-Year Revenue Growth -11.50%
5-Year Earnings Growth -163.33%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.06 on 11/07/24
Next Earnings Date N/A
Earnings Per Share ttm -0.37
EPS Growth vs. Prev Qtr 40.00%
EPS Growth vs. Prev Year 64.71%
Annual Dividend Yield 0.00%
Most Recent Dividend 1.750 on 06/15/09
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 03/26/09

MYGN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -4.51%
Return-on-Assets % -3.07%
Profit Margin % -34.96%
Debt/Equity 0.05
Price/Sales 1.59
Price/Cash Flow N/A
Price/Book 1.63
Book Value/Share 8.06
Interest Coverage -89.41

MYGN Dividends

Date Value
06/15/09 $1.7500
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar